ATR-258

DRUG2 trials

Sponsors

Atrogi AB, Morten Hostrup, PhD

Conditions

Overweight and ObesityType 2 Diabetes Mellitus

Phase 1

First-in-human Single and Multiple Dose Trial of ATR-258

CompletedNCT05409924

Atrogi ABType 2 Diabetes Mellitus

Start: 2022-04-11End: 2023-10-04Updated: 2023-12-18

Phase 2

Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle

Not yet recruitingNCT07421024

Morten Hostrup, PhDOverweight and Obesity

Start: 2026-02-20End: 2026-12-31Target: 10Updated: 2026-02-19

Related Papers

2865-LB: ATR-258, a GRK2-Biased ß2AR Modulator, Mitigates Worsening of Insulin Resistance in Type 2 Diabetes after Metformin Withdrawal

Diabetes2026-06-05